New York State Common Retirement Fund boosted its stake in The Medicines Company (NASDAQ:MDCO) by 36.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 254,492 shares of the company’s stock after acquiring an additional 68,195 shares during the period. New York State Common Retirement Fund’s holdings in The Medicines were worth $4,871,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Bank of Montreal Can raised its position in The Medicines by 31.9% in the fourth quarter. Bank of Montreal Can now owns 3,139 shares of the company’s stock worth $59,000 after acquiring an additional 760 shares during the period. First Mercantile Trust Co. raised its position in The Medicines by 21.6% in the fourth quarter. First Mercantile Trust Co. now owns 3,965 shares of the company’s stock worth $76,000 after acquiring an additional 705 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in The Medicines by 61.1% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,990 shares of the company’s stock worth $125,000 after acquiring an additional 2,651 shares during the period. CIBC Private Wealth Group LLC bought a new stake in The Medicines in the fourth quarter worth about $232,000. Finally, Riverhead Capital Management LLC raised its position in The Medicines by 32.2% in the third quarter. Riverhead Capital Management LLC now owns 12,306 shares of the company’s stock worth $368,000 after acquiring an additional 3,000 shares during the period.

Several brokerages have commented on MDCO. Goldman Sachs Group began coverage on shares of The Medicines in a research report on Thursday, December 13th. They issued a “neutral” rating and a $25.00 price objective on the stock. Wolfe Research started coverage on shares of The Medicines in a research report on Friday, December 14th. They issued an “outperform” rating on the stock. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Monday, December 31st. Finally, BidaskClub upgraded shares of The Medicines from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $45.00.

In other news, Director Alexander J. Denner acquired 325,000 shares of The Medicines stock in a transaction that occurred on Monday, March 4th. The stock was bought at an average price of $25.45 per share, with a total value of $8,271,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark Timney acquired 2,926 shares of The Medicines stock in a transaction that occurred on Friday, December 21st. The shares were purchased at an average cost of $17.90 per share, with a total value of $52,375.40. Following the purchase, the chief executive officer now owns 29,789 shares of the company’s stock, valued at approximately $533,223.10. The disclosure for this purchase can be found here. Insiders bought 856,389 shares of company stock valued at $20,246,298 in the last quarter. Corporate insiders own 10.29% of the company’s stock.

MDCO opened at $27.13 on Friday. The stock has a market capitalization of $2.00 billion, a PE ratio of -9.32 and a beta of 1.29. The company has a debt-to-equity ratio of 31.23, a current ratio of 5.05 and a quick ratio of 5.03. The Medicines Company has a twelve month low of $16.69 and a twelve month high of $41.57.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, February 27th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.05). The Medicines had a negative return on equity of 2,119.03% and a negative net margin of 668.93%. During the same quarter in the previous year, the company posted ($0.61) earnings per share. On average, equities research analysts anticipate that The Medicines Company will post -1.64 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “New York State Common Retirement Fund Increases Holdings in The Medicines Company (MDCO)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/new-york-state-common-retirement-fund-increases-holdings-in-the-medicines-company-mdco/2896881.html.

About The Medicines

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: What is a Futures Contract?

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.